Taxotere

Advance Directives, Advance Directives, Metastatic Hormone-Refractory Prostate Cancer + 13 more
Treatment
12 FDA approvals
20 Active Studies for Taxotere

What is Taxotere

DocetaxelThe Generic name of this drug
Treatment SummaryDocetaxel is an anti-cancer drug used to treat breast, ovarian, and non-small cell lung cancer. The medication works by binding to a protein found in cells called tubulin, which stops the growth of cancer cells.
Taxotereis the brand name
image of different drug pills on a surface
Taxotere Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Taxotere
Docetaxel
2008
97

Approved as Treatment by the FDA

Docetaxel, also known as Taxotere, is approved by the FDA for 12 uses such as Non-Small Cell Lung Carcinoma and metastatic untreated non small cell lung cancer .
Non-Small Cell Lung Carcinoma
metastatic untreated non small cell lung cancer
Used to treat metastatic untreated non small cell lung cancer in combination with Cisplatin
Malignant Neoplasms
Used to treat Node Positive Breast Cancer in combination with Cyclophosphamide
Metastatic Breast Cancer
Advance Directives
Used to treat locally advanced untreated non small cell lung cancer in combination with Cisplatin
Advance Directives
Neoplasm Metastasis
Advance Directives
Used to treat advanced untreated gastric adenocarcinoma in combination with Cisplatin
Metastatic Hormone-Refractory Prostate Cancer
Used to treat refractory, metastatic hormone-refractory Prostate cancer in combination with Prednisone
Advance Directives
Used to treat locally advanced Squamous cell carcinoma of head and neck in combination with Cisplatin
Squamous Cell Carcinoma of Head and Neck
BRCA1 gene

Effectiveness

How Taxotere Affects PatientsDocetaxel is a drug used to treat cancer. It helps create and stabilize microtubules, which are necessary for many cell functions. Docetaxel also changes the way microtubules are organized, which can prevent cancer cells from dividing and growing.
How Taxotere works in the bodyDocetaxel stops cancer cells from reproducing by blocking the growth of their microtubules. This is done by locking the "building blocks" of microtubules (tubulin) in place, preventing them from moving around. This interferes with cell function, as this movement of microtubules is important for transporting chromosomes during mitosis (cell division). Additionally, docetaxel works by binding to a protein called Bcl-2, which stops cells from undergoing programmed cell death (apoptosis). By binding to this protein, docetaxel prevents it from working and allows the cell to die.

When to interrupt dosage

The advised dosage of Taxotere is contingent upon the determined condition, for example, Esophageal Cancer, Neoplasm Metastasis and Non-Small Cell Lung Carcinoma. The measure of dosage deviates, in accordance with the approach of administration (e.g. Intravenous or Injection, solution, concentrate - Intravenous) presented in the following table.
Condition
Dosage
Administration
Advance Directives
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
metastatic untreated non small cell lung cancer
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Small Cell Lung Cancer
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Metastatic Bladder Cancer
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Soft Tissue Sarcoma
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Non-Small Cell Lung Carcinoma
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
BRCA1 gene
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Sarcoma
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Metastatic Breast Cancer
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Advance Directives
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Squamous Cell Carcinoma of Head and Neck
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Neoplasm Metastasis
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Advance Directives
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Metastatic Hormone-Refractory Prostate Cancer
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Advance Directives
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Malignant Neoplasms
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous

Warnings

Taxotere has one contraindication and should not be used when encountering the conditions contained in the following table.Taxotere Contraindications
Condition
Risk Level
Notes
neutrophil count <1500 cells/mm3
Do Not Combine
There are 20 known major drug interactions with Taxotere.
Common Taxotere Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Docetaxel.
Abetimus
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with Acteoside.
Taxotere Toxicity & Overdose RiskThe most toxic dose of this drug in rats is greater than 2000mg/kg. An overdose could lead to problems with the bone marrow, peripheral nerve damage, and irritation of the mucous membranes. Two people who overdosed on this drug experienced severe low white blood cell counts, fatigue, skin reactions, and tingling. They both recovered without any major problems.
image of a doctor in a lab doing drug, clinical research

Taxotere Novel Uses: Which Conditions Have a Clinical Trial Featuring Taxotere?

378 active trials are being conducted to assess the potential of Taxotere to combat metastatic untreated non small cell lung cancer, Sarcoma and Advance Directives.
Condition
Clinical Trials
Trial Phases
Neoplasm Metastasis
1 Actively Recruiting
Phase 2
Metastatic Hormone-Refractory Prostate Cancer
88 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Metastatic Breast Cancer
94 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1
Soft Tissue Sarcoma
65 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1
Advance Directives
0 Actively Recruiting
Squamous Cell Carcinoma of Head and Neck
9 Actively Recruiting
Phase 1, Phase 2
metastatic untreated non small cell lung cancer
0 Actively Recruiting
Small Cell Lung Cancer
59 Actively Recruiting
Phase 2, Phase 3, Phase 1, Not Applicable, Early Phase 1
Advance Directives
0 Actively Recruiting
Advance Directives
0 Actively Recruiting
Advance Directives
0 Actively Recruiting
BRCA1 gene
12 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1
Sarcoma
1 Actively Recruiting
Phase 2
Metastatic Bladder Cancer
3 Actively Recruiting
Phase 2, Phase 1, Not Applicable
Non-Small Cell Lung Carcinoma
0 Actively Recruiting
Malignant Neoplasms
1 Actively Recruiting
Not Applicable

Taxotere Reviews: What are patients saying about Taxotere?

4.7Patient Review
8/8/2016
Taxotere for Breast Cancer
I was diagnosed with Triple Negative Breast Cancer and started Taxotere immediately. Almost all of my hair fell out, as well as my nails. The nail beds turned black and now, 3 months later, the nails are coming off. My hair is slowly growing back but it's a different texture. I didn't have any unexpected side effects which was great.
3.7Patient Review
4/13/2015
Taxotere for Cancer of Prostate that has Spread to Other Part of Body
I've only had 2 out of 6 infusions. Too early to tell if its effective. Will update after next PSA test. My tolerance is very good. The only negatives were an early swelling of hands (now OK) and fatigue; both side affects have improved since then, however.
3.3Patient Review
6/29/2011
Taxotere for Cancer of Prostate that has Spread to Other Part of Body
I've only just started taking this medication, so I don't have a ton of information yet.
3.3Patient Review
3/3/2010
Taxotere for Breast Cancer
3.3Patient Review
1/31/2013
Taxotere for Cancer Involving the Head or Neck
2003 is when I was treated with this drug. I had an allergic reaction in which my feet burned like I walked on hot coals. I could not walk and soon layers and layers of the skin peeled off and lost toenails and finger nails and all the skin on my hands. Ever since I have had severe nerve damage. I do not have active cancer however. They did switch me to Taxol to finish my treatments.
2.7Patient Review
8/18/2011
Taxotere for Non-Small Cell Lung Cancer
Taxotere caused me significant and permanent damage to my lungs. If you find yourself short of breath after this treatment, please get examined by a doctor immediately.
2.7Patient Review
3/5/2010
Taxotere for Non-Small Cell Lung Cancer
2.3Patient Review
7/20/2011
Taxotere for Breast Cancer that has Spread to Another Part of the Body
I've had three infusions of this treatment. While it has been successful in reducing my PSA levels, I have also had reactions to it during the infusion process that have caused chest and neck pain.
2Patient Review
9/11/2011
Taxotere for Breast Cancer
I constantly had diarrhea, felt nauseous, and experienced chronic pain in my muscles and joints.
2Patient Review
3/14/2014
Taxotere for Non-Small Cell Lung Cancer
i had every side effect mentioned, great for working on cancer, horable working on you it's a killer. wound up with chf,copd,more lung trouble. took myself off the drug after 9 sessions. now trying to rehab.
1Patient Review
7/22/2010
Taxotere for Cancer Involving the Head or Neck
I've been taking Taxotere for seven months now, and the constant eye tearing and fingernail infections are really getting to me. My CT scans have shown "slight improvement," but I'm not sure if that's worth the side effects. I'm planning on discussing a change in treatment with my oncologist at my next appointment.
1Patient Review
6/18/2014
Taxotere for Breast Cancer
I had my 1st TCH on 6/11/14. Within 12 hours, I was in excruciating pain from lower back to knees. The pain lasted 3 days. On day 6, my infusion arm started turning red and itching. Day 7, I have a rash on my infusion hand/wrist that is red and itchy. My mouth and tongue are swollen and I have sores on the sides of my tongue. I have 5 more rounds to go. I am meeting with my Oncologist before my next treatment on 7/1/14. Praying he will change my treatment plan!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about taxotere

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Taxotere?

"-Side effects such as pain or swelling at the injection site, nausea, vomiting, diarrhea, excessive tearing, fatigue, dizziness, drowsiness, feeling drunk, constipation, and loss of appetite may occur.

-Temporary hair loss and nail changes may also occur.

-This medication can decrease your body's ability to fight an infection."

Answered by AI

What is the most common side effect of docetaxel?

"Two common long-term side effects of docetaxel chemotherapy are sensory and motor peripheral neuropathy, which are less severe than with paclitaxel. Grade 3 and 4 neuropathy is only observed in less than 10% of patients receiving docetaxel therapy."

Answered by AI

How long can you take Taxotere?

"Health care providers give Taxotere to their patients through an IV. The IV takes one hour to administer the drug, and this happens every three weeks. Depending on the type of cancer, the patient may have to go through several cycles of this treatment."

Answered by AI

Is Taxotere a strong chemo drug?

"Because Taxotere is a strong chemotherapy drug, its side effects tend to be more extreme than drugs that treat other, less serious issues. To deal with these side effects, doctors may lower the dose or prescribe drugs that reduce the risk of allergic reactions."

Answered by AI

Clinical Trials for Taxotere

Have you considered Taxotere clinical trials? We made a collection of clinical trials featuring Taxotere, we think they might fit your search criteria.
Have you considered Taxotere clinical trials? We made a collection of clinical trials featuring Taxotere, we think they might fit your search criteria.
Have you considered Taxotere clinical trials? We made a collection of clinical trials featuring Taxotere, we think they might fit your search criteria.